Consti’s Q3/24 figures were in line with our estimates.
Redeye comments on Nitro Games' Q3 2024 report, which was stronger than expected, both in terms of s...
Enea’s report aligned with Redeye’s estimates (RRe) on a constant currency basis.
Gapwaves announced a supply agreement and joint development with Valeo (previously undisclosed Europ...
Vitrolife delivered a consecutive positive organic growth recovery with 7% organic growth in constan...
Redeye makes slight adjustments to its forecasts following Xbrane's Q3 report, which indicated conti...
The company's Q3 net sales and adjusted EBIT were close to LSEG Data & Analytics consensus.
Ahead of Cibus' Q3 report, we include the acquisition of eight properties in Denmark and Finland, an...
Redeye maintains its fair value range for Sleep Cycle following the Q3 2024 quarterly report, which ...
During Q3, Svedberg Group once again demonstrated the strength of its risk-balanced portfolio.
Redeye retains its Base Case following a solid Q3 report, slightly beating our forecasts on EBITA.
Redeye thinks that Lagercrantz reported another stable quarter in a challenging market.
Redeye takes a positive stance towards Fortnox following a solid Q3 report, with strong net customer...
Redeye retains its positive view of Carasent following the Q3 report.
- Q3 trading update and reiterated FY guidance... - .
- OEM and AM challenges to normalise in Q1'25e - '24e-'26e EBIT down 18-3%; 20% CAGR '23-'26e - 30-1...
- ~40% y-o-y order intake growth in Q3 provides visibility - Minor positive estimate revisions - NTM...
- Cyclical, variable volumes behind miss & soft near-term outlook - We cut '25e and '26e adj.
- Q3 EBITA 3% above IR consensus, 5% above ABGSCe - Focus on continued strong trend in Medical Solut...
- Slower recovery, but positive gross margin trend - We lower '24e-'26e adj.
